Skip to main content
Log in

Gut microbiota in 2022

Nifty new tools for microbiome treatment design

  • Year in Review
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

The gut microbiome field is shifting from association to modulation. Microbiota-based treatments come in many shapes and sizes, ranging from dietary intervention to live bacterial products. Recent methodological advances are instrumental to developing innovative new treatment strategies in microbiome-linked pathologies.

Key advances

  • Isotope tracing enabled mapping of nutrient routes in the mouse gut microbiota in vivo3.

  • Engineered Escherichia coli strains enable in vivo recording of transcriptional responses throughout the murine gastrointestinal tract5.

  • CRISPR-edited lactococci encoding β-lactamases control microbiota damage of ampicillin treatment, lowering susceptibility to Clostridioides difficile in mouse models6.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Tools for microbiome innovation.

References

  1. Gilbert, J. A. et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 535, 94–103 (2016).

    Article  CAS  Google Scholar 

  2. Tramontano, M. et al. Nutritional preferences of human gut bacteria reveal their metabolic idiosyncrasies. Nat. Microbiol. 3, 514–522 (2018).

    Article  CAS  Google Scholar 

  3. Zeng, X. et al. Gut bacterial nutrient preferences quantified in vivo. Cell 185, 3441–3456.e19 (2022).

    Article  CAS  Google Scholar 

  4. Vieira-Silva, S. et al. Species–function relationships shape ecological properties of the human gut microbiome. Nat. Microbiol. 1, 16088 (2016).

    Article  CAS  Google Scholar 

  5. Schmidt, F. et al. Noninvasive assessment of gut function using transcriptional recording sentinel cells. Science 376, eabm6038 (2022).

    Article  CAS  Google Scholar 

  6. Cubillos-Ruiz, A. et al. An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis. Nat. Biomed. Eng. 6, 910–921 (2022).

    Article  CAS  Google Scholar 

  7. Pan, M. et al. Genomic and epigenetic landscapes drive CRISPR-based genome editing in Bifidobacterium. Proc. Natl Acad. Sci. USA 119, e2205068119 (2022).

    Article  CAS  Google Scholar 

  8. He, M. et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45, 109–113 (2013).

    Article  CAS  Google Scholar 

  9. Rubin, B. E. et al. Species- and site-specific genome editing in complex bacterial communities. Nat. Microbiol. 7, 34–47 (2022).

    Article  CAS  Google Scholar 

  10. Lam, K. N. et al. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep. 37, 109930 (2021).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

J.R. thanks the Raes lab, and especially N. Prochazkova, for enticing scientific discussions contributing to this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeroen Raes.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raes, J. Nifty new tools for microbiome treatment design. Nat Rev Gastroenterol Hepatol 20, 77–78 (2023). https://doi.org/10.1038/s41575-022-00735-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-022-00735-2

  • Springer Nature Limited

Navigation